Omalizumab is the only anti-IgE antibody approved to date and is restricted to serve as a third-line add-on therapeutic for moderate-to-severe persistent allergic asthma (approved 2003), chronic spontaneous urticaria (CSU) (approved 2014), and nasal polyps (approved 2020) (30). Here, IGHE is linked to allergic asthma.